GLMD Rasio cepet Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals (GLMD) generates revenue by introducing anti-fibrosis and NASH treatments to the US market, specifically the drug Aramchol. Simultaneously, Galmed Pharmaceuticals (GLMD) adheres to environmental standards by modernizing wastewater treatment and energy consumption within its laboratories. This price chart reflects a quick ratio of 4.29. However, its speculative status and fierce competition in the hepatology sector, coupled with a lack of active sales, weaken the business's market position.

For Galmed Pharmaceuticals (GLMD), the availability of capital to conduct clinical trials for Aramchol is a critical stability factor. Quick liquidity measures the company's ability to settle short-term obligations using cash and accounts receivable, completely excluding illiquid inventory. It is essential for investors to monitor this ratio to assess the risk of a cash crunch prior to the platform's licensing. Analyzing solvency dynamics excluding inventory provides an objective assessment of the business's financial autonomy.